Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design

NCT05085028 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT05085028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05085028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design
Lead sponsor
Imperial College London
Phase
Phase 3
Overall status
Recruiting
Start date
June 23, 2022
Completion date
May 31, 2027
Enrollment
1,750 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nonsmall cell